Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Celldex Therapeutics, Inc. (CLDX) had Income from Continuous Operations of $-81.32M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$0.12M |
|
$-81.32M |
|
-- |
|
$0.12M |
|
$87.27M |
|
$-87.15M |
|
$5.84M |
|
$-81.32M |
|
$-81.32M |
|
$-81.32M |
|
|
Income from Continuous Operations |
$-81.32M |
$-81.32M |
|
$-81.32M |
|
$-87.15M |
|
$-87.22M |
|
66.42M |
|
66.42M |
|
$-1.23 |
|
$-1.23 |
|
| Balance Sheet Financials | |
$534.66M |
|
$5.33M |
|
$48.32M |
|
$582.98M |
|
$50.99M |
|
-- |
|
$4.83M |
|
$55.82M |
|
$527.16M |
|
$499.98M |
|
$527.16M |
|
66.55M |
|
| Cash Flow Statement Financials | |
$-210.94M |
|
$209.07M |
|
$2.39M |
|
$28.36M |
|
$28.87M |
|
$0.52M |
|
$36.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.49 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
100.00% |
|
-72628.38% |
|
-72628.38% |
|
-- |
|
-67764.20% |
|
-67764.17% |
|
$-213.66M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.06 |
|
1511.25 |
|
-15.43% |
|
-16.26% |
|
-13.95% |
|
-15.43% |
|
$7.92 |
|
$-3.22 |
|
$-3.18 |
|